DRAVP ID Name Description Disease Pubchem ID
DRAVPc001 Brilacidin Brilacidin is a synthetic, nonpeptidic, small molecule mimetic of defensin, a type of host defense proteins/peptides (HDPs) or antimicrobial peptides (AMPs), with potential antibacterial and antiviral activities. Upon administration, brilacidin selectively destabilizes bacterial and viral membrane integrity, which leads to their proteolysis and degradation. HDPs are part of the innate immune response and act as the first line of defense against foreign pathogens. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been shown to suppress defensins. COVID-19 25023695
DRAVPc002 Boceprevir Boceprevir is a hepatitis C virus NS3/4A protease inhibitor used in combination with other medications to treat chronic hepatitis C genotype 1 infection. Initially approved for use in 2012, it was withdrawn in 2015 because of the availability of more effective and better tolerated all oral regimens of direct acting antiviral agents. Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b. Chronic HCV infection 10324367
DRAVPc003 Plitidepsin(Aplidine) Plitidepsin is a didemnin that is didemin B in which the hydroxy group of the 1-(2-hydroxypropanoyl)-L-prolinamide moiety has been oxidised to the corresponding ketone. It was originally isolated from the Mediterranean tunicate Aplidium albicans. It has a role as a marine metabolite, an antineoplastic agent and an anticoronaviral agent. Chronic HCV infection 3010818
DRAVPc004 Enfuvirtide(Fuzeon, DP178) Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. By disrupting the HIV-1 molecular machinery during its final stage of fusion with the target cell, enfuvirtide limits the spread of further infection. HIV Infections 16130199
DRAVPc005 Sifuvirtide Sifuvirtide is a linear 36-amino acid residues anti-HIV peptide, which designed based on the 3D structure of the HIV-1 gp41 fusogenic core conformation. HIV Infections 49769437
DRAVPc006 Fibrin-derived peptide FX-06 is a fibrin-derived synthetic peptide used for treatment of vascular leak syndrome in Ebola virus disease, Phase 2 trials for COVID-19 treatment. COVID-19 16208062
DRAVPc007 Albuvirtide Albuvirtide (ABT) belongs to the class of HIV-1 fusion inhibitors. It is a 3-maleimimidopropionic acid (MPA)-modified peptide derived from the C-terminal heptad repeat sequence of HIV-1 gp41. It binds to gp41, blocking HIV-1 from entering and infecting certain cells HIV infection 134694278
DRAVPc008 Alisporivir(Debio-025) Alisporivir is a non-immunosuppressive analogue of cyclosporine A and an inhibitor of cyclophilins, with potential antiviral activity. Upon oral administration, alisporivir targets and inhibits human host cyclophilins, thereby inhibiting hepatitis C virus (HCV) replication in hepatocytes. Alisporivir may also inhibit the replication of various coronaviruses. In addition, it may inhibit mitochondrial cyclophilin-D, which regulates mitochondrial permeability transition pore (mPTP) opening. This may prevent cell death and tissue damage. It has a role as an anticoronaviral agent. Chronic HCV infection, COVID-19 11513676
DRAVPc009 Thymalfasin A thymus hormone polypeptide found in thymosin fraction 5 (a crude thymus gland extract) but now produced by synthesis.Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression, and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients. HBV infection, HCV infection 16130571
DRAVPc010 Golotimod Golotimod(SCV-07) is a novel synthetic dipeptide containing the amino acids D-glutamine and L-tryptophan, which is used to treat hepatitis C by oral administration. SCV-07 has shown efficacy in treating various viral and bacterial infections. Chronic HCV infection 6992140
First 1 2 3 4 5 6 7 Last